看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
3 _5 J/ ~6 ?- y% {5 K3 s0 M1 Z( w# @: W2 f* y( Z: J* g! O
8 N9 ^2 Y2 o2 T* G4 e& {' sCurrently available feasibility data for possible combination strategies.
0 K. a% R) v# S! j, ~% a' x5 A0 q5 @————————————————————————————————6 _/ _- c3 ]8 g+ B u
Combination Feasibility according to preliminary data ( Z* q' v z7 n: i' o$ b
——————————————————————————————————
0 M: F p* }* U! Y) L3 `0 F$ ]Bevacizumab + sorafenib Yes, reduced dose . ~( r; s, Z- z( \% v
Bevacizumab + sunitinib† No : ^1 X7 y+ h" `% j; q
Bevacizumab + temsirolimus Yes
: `+ f: j" S; O5 LBevacizumab + everolimus Yes 2 [$ m, ]6 x/ q, d
Sorafenib + sunitinib ? * Z r2 ?$ K( h
Sorafenib + temsirolimus Yes, reduced dose 2 M0 S2 J6 X7 w$ ?
Sorafenib + everolimus Yes, reduced dose 8 d- C3 T* I; K6 e
Sunitinib + temsirolimus† No
& V4 D. E- B4 w8 F8 W: vSunitinib + everolimus ? 2 h. W9 W$ K$ ^ l* Z/ v
Temsirolimus + everolimus ?
# K, Y. y; d* c: |# s& l————————————————————
( n8 A" g9 i5 z. J5 E0 y4 X! L†Led to US FDA warning.
- _! c2 W& J( \8 ]: L, Y?: As yet unattempted combination.
, n; ~' E# x9 G3 O2 v0 |) ^" c8 E$ n |